Apoha has emerged from stealth with USD $36 million in funding led by Singular.
The London-based company is building a new data layer to measure how molecules and materials behave under real-world conditions, targeting applications in pharmaceuticals, food, materials and physical-world artificial intelligence.
Draper Associates joined the round, alongside continued backing from Redalpine, Seedcamp, Wilbe and Nucleus. Apoha also received grant funding from Innovate UK.
The funding will be used to develop what Apoha calls Liquid State Intelligence, which it describes as empirical data on molecular behaviour. The company argues this information has been largely missing from conventional approaches, which tend to focus on molecular sequence and structure rather than how substances respond under stress or in changing environments.
The science
Apoha traces its origins to research begun by founder and Chief Executive Officer Shamit Shrivastava in 2008. That work examined the physics at the boundary where matter meets liquids and led to a method for measuring how molecules interact, change over time and respond to external conditions.
Shrivastava co-founded the business in 2021 with Anshika Srivastava, Apoha’s Chief Operating Officer and a former Executive Director at Goldman Sachs. The company says it now holds more than 60 patents across hardware, software, data and AI models.
Its first product, VIBE, short for Variations in Inter-facial Behaviour Under Excitation, uses a very small sample suspended in liquid, applies a controlled series of stresses and records the resulting wave patterns in real time.
According to Apoha, those measurements produce more than 1,000 descriptors of behaviour. The aim is to offer a single readout that captures several aspects of molecular performance that would otherwise require separate tests.
Commercial use
Apoha says the platform is already being used commercially, including by Boehringer Ingelheim and Somru BioSciences. It is also working with multiple Fortune 500 companies in pharmaceuticals, food and beverage, and materials.
Joint research with Boehringer Ingelheim, which Apoha described as a multi-year commercial partner, showed the platform identifying high-risk antibody candidates with greater than 90% precision from 8 micrograms of material. In a separate benchmarking exercise on a dataset of 236 clinical antibodies, Apoha says its system outperformed 12 industry-standard tests used by pharmaceutical companies.
For Ethris, a German biotech company, Apoha says it is working on methods to improve in-vitro to in-vivo correlation to predict how lipid nanoparticles carrying mRNA behave in animals. In food, it says plant-based brand THIS used the technology to find a protein replacement for a supermarket product.
Apoha’s pitch rests on the argument that poor visibility into molecular behaviour creates costly uncertainty for industry. Drug developers, food makers and materials companies often make decisions without enough evidence about how products will perform outside narrow laboratory conditions, it argues.
That gap has also become relevant to AI groups seeking to build systems that operate in the physical world. Apoha says existing AI models have been trained extensively on language, images and code, but not on structured datasets that describe how matter behaves.
“Liquid State Intelligence took 15 years of science and 5 years of company-building to bring to life. There is no shortcut to this data class – it cannot be scraped from the internet, synthesised, or retrofitted from existing assays. It has to be measured. Where sequence gave us the language of biology and structure the language of design, Liquid State Intelligence gives us the language of behaviour – what matter, molecules and materials actually do – and we are the company building it,” said Shamit Shrivastava, Chief Executive Officer and Co-Founder of Apoha.
Anshika Srivastava set out the company’s view of the broader market.
“Machines have learned to see what matter looks like and to read what we say about it. They have not learned to taste, smell or feel matter – to perceive how a drug dissolves, how a flavour holds, how a material wears. That is the layer we are building. Liquid State Intelligence will be to physical-world AI what sequence was to genomics, the data without which nothing else works,” said Srivastava.
Investors said commercial traction was central to the deal. Singular, a European early-stage venture capital firm, said Apoha stood out for turning academic research into a product already in use by pharmaceutical companies.
“Apoha represents a new generation of European scientific companies where AI is not a future promise, but a practical tool already transforming how biology is done. What excited us immediately was the team’s ability to turn world-class research into a product that pharma companies can use today to dramatically accelerate R&D. For the first time in 25 years, we are back to creating genuinely new science, being commercialised by founders with drive and global ambition,” said Raffi Kamber, Co-Founder and General Partner at Singular.
